Program
GSK4771261
A development code.
In GlaxoSmithKline's pipeline, Monoclonal antibody against novel kidney target
. Its studies are mostly in Kidney Diseases · Polycystic Kidney, Autosomal Dominant, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 22 open or running | phase 1since Dec 11, 2024 | Dec 11, 2024 | May 20, 2027phase 1 · NCT07600450 |
- Named in GlaxoSmithKline’s own pipeline as
GSK4771261
, phase 1, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 11, 2024First study: phase 1 study in Kidney DiseasesFirst studyNCT06734234 · 86 enrolled · United States, Belgium, Canada and more
- May 14, 2026Phase 1 study in Kidney DiseasesNCT07600450 · 30 planned · Netherlands
- Oct 5, 2026Primary completion moved from 2026-09-22 to 2027-05-20Date moved laterphase 1 · +8 months · NCT07600450
Ahead
- May 20, 2027Primary completion: phase 1 study in Kidney DiseasesNCT07600450
- Jul 23, 2027Primary completion: phase 1 study in Kidney DiseasesNCT06734234
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Monoclonal antibody against novel kidney target”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07600450Kidney Diseases · Netherlands | 1 | Recruiting | May 20, 2027 | 30 |
| NCT06734234Kidney Diseases · United States, Belgium, Canada and more | 1 | Active, not recruiting | Jul 23, 2027 | 86 |
How it is read
Names in the registry
- “GSK4771261”, 2 entries
Codes read as this program: GSK4771261.
Conditions, from the studies’ own filings
- Kidney Diseases, 1 study
- Polycystic Kidney, Autosomal Dominant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.